SpringerLink
Log in

The Value of Tumor Sample Analyses Before and After Checkpoint Inhibition: Contextualizing the Treatment-Induced Changes in Gene Expression

  • Chapter
  • First Online:
Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers

  • 429 Accesses

Abstract

Although neoadjuvant cisplatin-based chemotherapy prior to radical cystectomy is the current standard of care for muscle-invasive bladder cancer (MIBC), immune checkpoint inhibitors have shown promising results in this setting. Phase II and III data of neoadjuvant programmed cell death-1 (PD-1) receptor/PD-1 ligand (PD-L1) inhibitors are now available with biomarker analyses of pre- and posttreatment tumors to help guide precision-based treatment to individual tumors. While still in its infancy, this review of available neoadjuvant immunotherapy trials (PURE-01, ABACUS, NABUCCO) and their biomarker analyses can contextualize the molecular and immunology-based biomarkers to improve prediction of individual patient response and outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
EUR 29.95
Price includes VAT (Germany)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
EUR 93.08
Price includes VAT (Germany)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
EUR 117.69
Price includes VAT (Germany)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
EUR 160.49
Price includes VAT (Germany)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66.

    Article  CAS  PubMed  Google Scholar 

  2. Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol. 2017;198(3):552–9.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Alfred Witjes J, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71(3):462–75.

    Article  CAS  PubMed  Google Scholar 

  4. Chism DD, Woods ME, Milowsky MI. Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer. Oncologist. 2013;18(8):933–40.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Sonpavde G, Goldman BH, Speights VO, Lerner SP, Wood DP, Vogelzang NJ, et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009;115(18):4104–9.

    Article  PubMed  Google Scholar 

  6. Burger M, Mulders P, Witjes W. Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: results of a feasibility questionnaire. Eur Urol. 2012;61(5):1070–1.

    Article  PubMed  Google Scholar 

  7. Duplisea JJ, Mason RJ, Reichard CA, Li R, Shen Y, Boorjian SA, et al. Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma. Can Urol Assoc J. 2019;13(2):24–8.

    PubMed  PubMed Central  Google Scholar 

  8. Balar AV, Castellano D, O’Donnell PH, Grivas P, Vuky J, Powles T, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(11):1483–92.

    Article  CAS  PubMed  Google Scholar 

  9. Alva A, Csőszi T, Ozguroglu M, Matsubara N, Geczi L, Cheng SY-S, et al. LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361. Ann Oncol. 2020;31:S1155.

    Article  Google Scholar 

  10. Galsky MD, Arija JÁA, Bamias A, Davis ID, De Santis M, Kikuchi E, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10236):1547–57.

    Article  CAS  PubMed  Google Scholar 

  11. Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucianò R, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J Clin Oncol. 2018;36(34):3353–60.

    Article  CAS  PubMed  Google Scholar 

  12. Necchi A, Raggi D, Gallina A, Madison R, Colecchia M, Lucianò R, et al. Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur Urol. 2020;77(4):439–46.

    Article  CAS  PubMed  Google Scholar 

  13. Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med. 2019;25(11):1706–14.

    Article  CAS  PubMed  Google Scholar 

  14. van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit LA, de Feijter JM, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med. 2020;26(12):1839–44.

    Article  PubMed  Google Scholar 

  15. Jubel JM, Barbati ZR, Burger C, Wirtz DC, Schildberg FA. The role of PD-1 in acute and chronic infection. Front Immunol [Internet]. 2020 [Cited 2020 Oct 7];11. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105608/.

  16. Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer J. 2018;24(1):47–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Torlakovic E, Lim HJ, Adam J, Barnes P, Bigras G, Chan AWH, et al. “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Mod Pathol. 2020;33(1):4–17.

    Article  PubMed  Google Scholar 

  18. ESMO Virtual Congress 2020: invited discussant: optimizing first-line treatment in metastatic urothelial carcinoma: is the fog clearing? [Internet]. Cited 2020 Oct 27. Available from: https://www.urotoday.com/conference-highlights/esmo-2020/bladder-cancer/124558-esmo-virtual-congress-2020-invited-discussant-optimizing-first-line-treatment-in-metastatic-urothelial-carcinoma-is-the-fog-clearing.html.

  19. Balar AV, Mahipal A, Grande E, et al. Abstract CT112: durvalumab + tremelimumab in patients with metastatic urothelial cancer. AACR Meet Abstr Online. 2018;78(13):supplement.

    Google Scholar 

  20. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76.

    Article  CAS  PubMed  Google Scholar 

  22. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee J-L, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Patel MR, Ellerton J, Infante JR, Agrawal M, Gordon M, Aljumaily R, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018;19(1):51–64.

    Article  CAS  PubMed  Google Scholar 

  24. Tsimafeyeu I, Imyanitov E, Zavalishina L, Raskin G, Povilaitite P, Savelov N, et al. Agreement between PDL1 immunohistochemistry assays and polymerase chain reaction in non-small cell lung cancer: CLOVER comparison study. Sci Rep. 2020;10(1):3928.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Erber R, Stöhr R, Herlein S, Giedl C, Rieker RJ, Fuchs F, et al. Comparison of PD-L1 mRNA expression measured with the CheckPoint Typer® assay with PD-L1 protein expression assessed with immunohistochemistry in non-small cell lung cancer. Anticancer Res. 2017;37(12):6771–8.

    PubMed  Google Scholar 

  26. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315–22.

    Article  Google Scholar 

  27. Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol. 2017;72(4):544–54.

    Article  CAS  PubMed  Google Scholar 

  28. Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol. 2014;11(7):400–10.

    Article  CAS  PubMed  Google Scholar 

  29. Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77(4):420–33.

    Article  PubMed  Google Scholar 

  30. Kardos J, Chai S, Mose LE, Selitsky SR, Krishnan B, Saito R, et al. Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. JCI Insight. 2016;1(3):e85902.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Sjödahl G, Lauss M, Lövgren K, Chebil G, Gudjonsson S, Veerla S, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012;18(12):3377–86.

    Article  PubMed  Google Scholar 

  32. Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52(1):17–35.

    Article  CAS  PubMed  Google Scholar 

  34. Necchi A, Raggi D, Gallina A, Ross JS, Farè E, Giannatempo P, et al. Impact of molecular subty** and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer. Eur Urol. 2020;77(6):701–10.

    Article  CAS  PubMed  Google Scholar 

  35. Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930–40.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Mezheyeuski A, Segersten U, Leiss LW, Malmström P-U, Hatina J, Östman A, et al. Fibroblasts in urothelial bladder cancer define stroma phenotypes that are associated with clinical outcome. Sci Rep. 2020;10(1):281.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Massagué J. TGFβ in cancer. Cell. 2008;134(2):215–30.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Wang L, Saci A, Szabo PM, Chasalow SD, Castillo-Martin M, Domingo-Domenech J, et al. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat Commun [Internet]. 2018 [Cited 2020 Oct 1];9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115401/.

Download references

Funding

J.J.M. is supported by Jesse Brown VA Medical Center, Chicago, IL (BX003692), and the Polsky Urologic Cancer Institute of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital.

Author information

Authors and Affiliations

  1. Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA

    Lauren Folgosa Cooley & Joshua J. Meeks

  2. Dxige Research Inc., Courtenay, BC, Canada

    A. Gordon Robertson

  3. Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA

    Joshua J. Meeks

  4. Department of Biochemistry and Molecular Genetics, Northwestern University, Chicago, IL, USA

    Joshua J. Meeks

  5. Departments of Urology and Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

    Joshua J. Meeks

Authors
  1. Lauren Folgosa Cooley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Gordon Robertson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joshua J. Meeks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joshua J. Meeks .

Editor information

Editors and Affiliations

  1. Medical Oncology and Urology, Vita-Salute San Raffaele University, Milano, Milano, Italy

    Andrea Necchi

  2. Department of Genitourinary Oncology, University of South Florida, Tampa, FL, USA

    Philippe E. Spiess

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Cooley, L.F., Robertson, A.G., Meeks, J.J. (2022). The Value of Tumor Sample Analyses Before and After Checkpoint Inhibition: Contextualizing the Treatment-Induced Changes in Gene Expression. In: Necchi, A., Spiess, P.E. (eds) Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers. Springer, Cham. https://doi.org/10.1007/978-3-030-80546-3_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-80546-3_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-80545-6

  • Online ISBN: 978-3-030-80546-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation